ライフサイエンスコーパス: fingolimod

1 ibitor of sphingosine kinase 1 (SK1) FTY720 (fingolimod).

2 efficacy after switching from IFNbeta-1a to fingolimod.

3 ften switch therapy to either natalizumab or fingolimod.

4 ly preceding switch to either natalizumab or fingolimod.

5 ent, interferon beta, glatiramer acetate, or fingolimod.

6 nth follow-up period after the initiation of fingolimod.

7 ts during the WP and after the initiation of fingolimod.

8 at clinically relevant therapeutic doses of fingolimod.

9 iosis for 12 days with CYM-5442, vehicle, or fingolimod.

10 erse events shifted towards that typical for fingolimod.

11 tential and mechanisms of neuroprotection by fingolimod.

12 ed (1:1) to receive either 0.5 mg or 1.25 mg fingolimod.

13 type IL-4 or of the clinically approved drug fingolimod.

14 e effects of immunomodulatory treatment with fingolimod.

15 The patients were clinically stable on fingolimod.

16 25 mg and 133 to placebo in cohort 1; 336 to fingolimod 0.5 mg and 354 to placebo in cohort 2).

17 53 (15%) of 358 patients given fingolimod 0.5 mg and 45 (13%) of 355 patients given pla

18 sisted of 336 patients randomly allocated to fingolimod 0.5 mg and 487 to placebo.

19 esults are presented here for the continuous-fingolimod 0.5 mg and pooled IFN-switch groups.

20 Fingolimod 0.5 mg caused more of the following adverse e

21 Fingolimod 0.5 mg is associated with a low incidence of

22 ng placebo or IFNbeta-1a IM were switched to fingolimod 0.5 mg therapy for study extensions.

23 Mean PBVC was -0.86 (SD 1.22) for fingolimod 0.5 mg versus -1.28 (1.50) for placebo (treat

24 1), corresponding to a reduction of 48% with fingolimod 0.5 mg versus placebo.

25 isability progression (hazard rate 0.83 with fingolimod 0.5 mg vs placebo; 95% CI 0.61-1.12; p=0.227)

26 e study (EOS), ARR in patients on continuous-fingolimod 0.5 mg was significantly lower than in the IF

27 patients: 370 to fingolimod 1.25 mg, 358 to fingolimod 0.5 mg, and 355 to placebo.

28 sing-remitting multiple sclerosis-to receive fingolimod 0.5 mg, fingolimod 1.25 mg, or placebo orally

29 patients were switched in a masked manner to fingolimod 0.5 mg, whereas those on placebo continued on

30 n onwards, patients were assigned to receive fingolimod 0.5 mg/day or placebo (cohort 2).

31 acebo and 0.21 (0.17-0.25) in patients given fingolimod 0.5 mg: rate ratio 0.52 (95% CI 0.40-0.66; p<

32 S study demonstrated significant benefits of fingolimod 0.5 or 1.25 mg over interferon beta-1a (IFNbe

33 as performed before and after treatment with fingolimod (0.3 mg/kg/d by mouth, 28 d) or vehicle as a

34 Patients received fingolimod (0.5, 1.25, or 5 mg/day), placebo, or intramu

35 Patients randomised to fingolimod (0.5/1.25 mg) in the core phase continued the

36 Participants received fingolimod (0.5/1.25 mg), placebo, or interferon beta fo

37 terferon beta (0.98 [0.65-1.49], p=0.93) and fingolimod (0.50 [0.25-1.01], p=0.18), and a lower proba

38 time curve) differed between natalizumab and fingolimod (-0.12 vs 0.04 per year, respectively, p < 0.

39 postmarketing setting, all patients received fingolimod, 0.5 mg/d (total exposure of 54,000 patient-y

40 infections in clinical trials were low with fingolimod, 0.5 mg/d, but higher than in placebo recipie

41 tween Sept 3, 2008, and Aug 30, 2011 (147 to fingolimod 1.25 mg and 133 to placebo in cohort 1; 336 t

42 Patients were initially assigned to fingolimod 1.25 mg per day or placebo (cohort 1); howeve

43 On Nov 12, 2009, all patients assigned to fingolimod 1.25 mg were switched to the 0.5 mg dose in a

44 and randomly allocated 1083 patients: 370 to fingolimod 1.25 mg, 358 to fingolimod 0.5 mg, and 355 to

45 patients with ME, 5 (26%), all treated with fingolimod 1.25 mg, had a history of uveitis compared wi

46 iple sclerosis-to receive fingolimod 0.5 mg, fingolimod 1.25 mg, or placebo orally once daily (1:1:1;

47 el of AD, the 5xFAD model, with two doses of fingolimod (1 and 5 mg/kg/day) and measured the response

48 Fingolimod (1) is the first approved oral therapy for th

49 In comparison to fingolimod (1), a full agonist of S1P(1) currently marke

50 ratio [HR] 0.66 [95% CI 0.36-1.22], p=0.37), fingolimod (1.27 [0.60-2.70], p=0.67), and natalizumab (

51 nburg, n = 64, fingolimod 88%; Umea, n = 36, fingolimod 19%), yielding a total cohort of N = 256 (fin

52 , 95% confidence interval [CI] = 23.7-48.3), fingolimod 28 (IR = 44.0, 95% CI = 29.2-63.5), and natal

53 ituximab and fingolimod (Stockholm, n = 156, fingolimod 51%; Gothenburg, n = 64, fingolimod 88%; Umea

54 od 19%), yielding a total cohort of N = 256 (fingolimod 55%).

55 n = 156, fingolimod 51%; Gothenburg, n = 64, fingolimod 88%; Umea, n = 36, fingolimod 19%), yielding

56 Post-LPS/HI administration of FTY720 (fingolimod), a sphingosine-1-phosphate receptor agonist

57 the sphingosine-1 phosphate receptor agonist fingolimod, a drug that crosses the blood-brain barrier.

58 Recently fingolimod, a functional S1P1 receptor antagonist, was i

59 It is well established that fingolimod, a modulator of the sphingosine-1-phosphate p

60 Fingolimod, a nonselective sphingosine-1-phosphate (S1P)

61 Fingolimod, a sphingosine-1-phosphate receptor agonist,

62 enesis of AD and the therapeutic benefits of fingolimod, a structural analog of sphingosine that is F

63 h multiple sclerosis (MS) (10 to <18 years), fingolimod administered for up to 2 years significantly

64 The direct impact of fingolimod administration was assessed via histochemical

65 syndrome, show decreased levels of BDNF, and fingolimod administration was found to partially rescue

66 at can also be activated in vivo by systemic fingolimod administration.

67 It is unknown whether fingolimod affects microglial activation in MS.

68 atients with MS switched from natalizumab to fingolimod after a mean of 31 natalizumab infusions (fem

69 neurons, underlie the beneficial effects of fingolimod after stroke.

70 ts given to MS patients: they are reduced by fingolimod, alemtuzumab, and dimethyl fumarate, whereas

71 Initial treatment with fingolimod, alemtuzumab, or natalizumab was associated w

72 lapsing-remitting MS, initial treatment with fingolimod, alemtuzumab, or natalizumab was associated w

73 acetate or interferon beta were escalated to fingolimod, alemtuzumab, or natalizumab within 5 years v

74 fficacy of the novel immunomodulator FTY720 (Fingolimod), alone and in combination with betamethasone

75 Fingolimod also decreased GFAP staining and the number o

76 Fingolimod also decreased infarct size in a rat model of

77 Fingolimod also readily penetrates the CNS, and fingolim

78 Further, the drug fingolimod also regulates the reactivity of glial cells,

79 FTY720 (fingolimod), an FDA-approved drug for treatment of multi

80 erosis (MS)-like lesion after treatment with fingolimod, an established MS therapy.

81 tudy examines whether topical application of fingolimod, an established SK/sphingosine-1-phosphate an

82 Fingolimod, an oral sphingosine 1-phosphate receptor mod

83 sing fingolimod treatment using search terms fingolimod and either rebound or reactivation.

84 domised patients, 107 each were treated with fingolimod and IFN beta-1a for up to 2 years.

85 Alemtuzumab seems superior to fingolimod and interferon beta in mitigating relapse act

86 Fingolimod and natalizumab therapies efficiently targete

87 had occurred in 232 and 338 patients in the fingolimod and placebo groups, respectively, resulting i

88 gs expand knowledge of the safety profile of fingolimod and strengthen evidence for its beneficial ef

89 irst-ever initiations of rituximab, 1,620 of fingolimod, and 1,670 of natalizumab in 6,136 MS patient

90 ts given interferon beta, 828 patients given fingolimod, and 1160 patients given natalizumab.

91 fectiveness of alemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsi

92 dings substantiate the beneficial profile of fingolimod as a disease-modifying agent in the managemen

93 s support a strong therapeutic potential for fingolimod as an acute rescue therapy for the treatment

94 The initial randomisation and dose of fingolimod assigned for the extension remained masked to

95 Fingolimod at 1 mg/kg/day provided better neuroprotectio

96 In clinical trials, patients received fingolimod at a dosage of 0.5 or 1.25 mg/d, interferon b

97 t study reveals that when applied topically, fingolimod attenuates both immediate and late-phase resp

98 The patients were switched to fingolimod because of safety reasons or therapy escalati

99 ants were included if they stopped receiving fingolimod between January 2014 and December 2015.

100 Importantly, fingolimod blocked the 2 activation events evoked in ast

101 Importantly, the treatment effect of fingolimod can be monitored in vivo by measuring the deg

102 Rates of VZV infections in fingolimod clinical trials are based on pooled data from

103 l population but a possibly higher risk with fingolimod compared to the general population (hazard ra

104 rates of infection were low but higher with fingolimod compared with placebo (11 vs 6 per 1000 patie

105 infection was higher for patients receiving fingolimod compared with those receiving other disease-m

106 a borderline-significant increased risk with fingolimod, compared to both the general population and

107 At 1 mg/kg/day, fingolimod decreased both peripheral blood lymphocyte co

108 Furthermore, fingolimod decreased interstitial fibrosis, cardiomyocyt

109 In mice at 3 months of age, we found that fingolimod decreased plaque density as well as soluble p

110 Fingolimod did not protect primary neurons against gluta

111 The anti-inflammatory effects of fingolimod did not slow disease progression in primary p

112 four approved oral compounds now available: fingolimod, dimethyl fumarate, teriflunomide, and cladri

113 rs, who received initial therapy with newer (fingolimod, dimethyl fumarate, teriflunomide, natalizuma

114 On withdrawal of fingolimod, drug-induced remission was lost and recrudes

115 ngosine-1-phosphate receptor activation with fingolimod during acute MI reduced infarct size via the

116 ngosine-1-phosphate receptor activation with fingolimod during acute myocardial infarction (MI) inhib

117 Furthermore, fingolimod efficacy in blocking astrocyte-mediated neuro

118 The Enquete Nationale sur l'Introduction du Fingolimod en Relais au Natalizumab (ENIGM) study, a sur

119 More importantly, fingolimod enhanced neurobehavioral recovery.

120 In conclusion, fingolimod exerts protective effects in a mouse model of

121 ic analgesics, supporting the repurposing of fingolimod for chronic pain treatment and energizing dru

122 Three percent stopped fingolimod for efficacy, tolerance, or compliance issues

123 Each patient received treatment with oral fingolimod for various durations.

124 ere we performed a dose-response study using fingolimod from 0.03 to 1 mg/kg/day in 5xFAD mice treate

125 Biomarkers predicting fingolimod (FTY) treatment response in relapsing-remitti

126 gosine 1-phosphate receptor (S1PR) modulator fingolimod (FTY720) ameliorated chronic progressive expe

127 own previously that the S1P receptor agonist fingolimod (FTY720) attenuates psychosine-induced glial

128 Treatment with fingolimod (FTY720) during the late phase of disease rev

129 Recently, the S1P analogue Fingolimod (FTY720) has been approved for the treatment

130 The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients resul

131 Fingolimod (FTY720) is an FDA-approved therapeutic drug

132 Recent studies have shown that fingolimod (FTY720) is neuroprotective in CNS injury mod

133 ssessed whether enhancing PP2A activity with fingolimod (FTY720) or 2-amino-4-(4-(heptyloxy) phenyl)-

134 argeting SET with a sphingolipid analog drug fingolimod (FTY720) or ceramide leads to the reactivatio

135 with either sphingosine kinase inhibitor or fingolimod (FTY720) significantly attenuated histamine-i

136 Fingolimod (FTY720) treatment of Y. enterocolitica-infec

137 Importantly, fingolimod (FTY720), a S1P analog recently approved for

138 tudy was designed to determine the impact of fingolimod (FTY720), a sphingosine-1-phosphate receptor

139 Fingolimod (FTY720), an FDA-approved immunomodulatory dr

140 hingosine-1-phosphate (S1P) receptor agonist fingolimod (FTY720), that has shown efficacy in advanced

141 (+) gammadeltaT17 cells egress from LNs in a fingolimod (FTY720)-sensitive manner and use C-C chemoki

142 FTY720 (Fingolimod, Gilenya) is a sphingosine analog used as an

143 nd Drug Administration-approved drug FTY720 (fingolimod, Gilenya) or vehicle control solution from 5

144 events occurred in 84 (25%) patients in the fingolimod group and 117 (24%) in the placebo group, inc

145 The fingolimod group had a lower mean annualized relapse rat

146 7.2% (95% CI 71.87-82.51) of patients in the fingolimod group versus 80.3% (73.31-87.25) of patients

147 phopenia occurred in 19 (6%) patients in the fingolimod group versus none in the placebo group, brady

148 le group were matched to 148 patients in the fingolimod group.

149 Fingolimod has been approved recently by the US Food and

150 In addition, fingolimod has recently been introduced as the first ora

151 Fingolimod has shown reductions in clinical and MRI dise

152 Oral active drugs such as fingolimod have been weighed down by safety concerns.

153 nd efficacy of switching from natalizumab to fingolimod have not yet been evaluated in a large cohort

154 follow-up, 7.6 years [IQR, 5.8-9.6]), as did fingolimod (HR, 0.37; 95% CI, 0.22-0.62; P < .001; 5-yea

155 se on IFNbeta-1a were re-randomised (1:1) to fingolimod (IFN-switch; IFN: 0.5/1.25 mg).

156 the preferential use of either rituximab or fingolimod in 2 of the centers mitigates these concerns.

157 reported that the neuroprotective effects of fingolimod in 5xFAD transgenic AD mice treated from 1-3

158 se of the study was to examine the effect of fingolimod in a mouse model of intracerebral hemorrhage.

159 t the administration of the therapy known as fingolimod in a mouse model of Krabbe's disease (namely,

160 ata suggest a potential therapeutic role for fingolimod in AD.

161 ese findings suggest that S1PR modulation by fingolimod in both the immune system and CNS, producing

162 Neuroprotective effects of fingolimod in mouse models of Parkinson's disease.

163 understanding of the mechanism of action of fingolimod in multiple sclerosis patients.

164 Fingolimod in paediatric MS was associated with consiste

165 We assessed the safety and efficacy of fingolimod in patients with primary progressive multiple

166 enerally consistent with those of studies of fingolimod in patients with relapse-onset multiple scler

167 alizumab is more effective than switching to fingolimod in reducing relapse rate and short-term disab

168 therefore tested the therapeutic effects of fingolimod in several rodent models of focal cerebral is

169 and tolerability of rituximab compared with fingolimod in stable RRMS patients who switch from natal

170 further assessed the efficacy and safety of fingolimod in such patients.

171 gned to receive 0.5 mg or 1.25 mg daily oral fingolimod in the core study continued with the same tre

172 t preclinical study examining the effects of fingolimod in twitcher mice, a murine model of Krabbe's

173 A neuroprotective effect of fingolimod in vivo may result from its inhibitory action

174 ntial of the immunosuppressive agent FTY720 (fingolimod) in hepatocellular carcinoma (HCC).

175 re phase continued the same dose (continuous-fingolimod) in the extension, whereas those on IFNbeta-1

176 In cultured neurons, fingolimod increases BDNF levels and counteracts NMDA-in

177 FTY720/fingolimod increases NPC1 and NPC2 expression and reduce

178 activity and MAPK signaling is required for fingolimod-induced BDNF increase, a pathway that can als

179 ibitors of both pathways, demonstrating that fingolimod-induced cardioprotection was mediated by repe

180 ummary, these data provide new insights into fingolimod-induced compositional changes of lymphocyte p

181 with the mononuclear cell-sequestering drug fingolimod influenced anti-CNS T cell responses in the C

182 reactivation during the WP or shortly after fingolimod initiation.

183 Patients had received fingolimod, interferon beta, or glatiramer acetate for a

184 Fingolimod is an effective treatment for relapsing-remit

185 witching from injectable immunomodulators to fingolimod is associated with fewer relapses, more favor

186 Although S1P1 agonist fingolimod is currently used for the treatment of multip

187 FTY720 (also called fingolimod) is recognized as an immunosuppressant and ha

188 osine-1-phosphate receptor modulator, FTY720/fingolimod, is approved for treatment of multiple sclero

189 Treatment with fingolimod led to a highly significant reduction in the

190 Switching from interferon beta-1a to fingolimod led to enhanced efficacy with no unexpected s

191 After switching to fingolimod (M0-12 vs M13-EOS), patients initially treate

192 m alone reduced pathological features as did fingolimod (maximally lymphopenic throughout), despite f

193 s, to our knowledge for the first time, that fingolimod may be repurposed to treat cutaneous inflamma

194 the Mecp2-deficient animals, suggesting that fingolimod may improve the functional output of the nerv

195 that, unlike the case in multiple sclerosis, fingolimod may potentially have therapeutic benefits in

196 ith multiple sclerosis treated with FTY-720 (fingolimod) may exhibit macular oedema.

197 tulated that anti-inflammatory mechanisms of fingolimod might also be protective in Alzheimer's disea

198 Importantly, fingolimod mitigated the development of adverse post-MI

199 18 years) were randomised to once-daily oral fingolimod (n=107) or once-weekly intramuscular IFN beta

200 patients were matched (natalizumab, n = 407; fingolimod, n = 171).

201 g DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or alemtuzumab.

202 After switching to fingolimod, numbers of new or newly enlarging T2 and gad

203 were found in 1.4% (rituximab) versus 24.2% (fingolimod) of magnetic resonance imaging examinations (

204 of natalizumab, 1.8% (rituximab) and 17.6% (fingolimod) of patients experienced a clinical relapse (

205 rodegeneration, and addressed the effects of fingolimod on astrocyte-neuron interaction and NO synthe

206 Although the effect of fingolimod on circulating lymphocyte subsets has been es

207 However, the effect of fingolimod on disability progression was more pronounced

208 We saw no effect of fingolimod on disability progression.

209 MRS also showed an effect of fingolimod on glutamate levels.

210 These protective effects of fingolimod on twitcher mice brain pathology was reflecte

211 The effects of fingolimod on twitching behavior and life span were also

212 g-remitting MS who were switching therapy to fingolimod or injectable immunomodulators up to 12 month

213 ls whereas this was not readily observed for fingolimod or monomethylfumarate.

214 th computer-generated blocks to receive oral fingolimod or placebo for at least 36 months and a maxim

215 Animals randomly received fingolimod or saline (control).

216 ophosphatidic acid but not by phosphate-free fingolimod or sphingosine or by phosphate-masked phospha

217 Fingolimod (or saline) was given 30 min after surgery an

218 udy therapies (alemtuzumab, interferon beta, fingolimod, or natalizumab), age 65 years or younger, Ex

219 monitored their frequencies in untreated and fingolimod- or natalizumab-treated patients with MS.

220 r the switch to natalizumab in comparison to fingolimod (p < 0.001).

221 golimod also readily penetrates the CNS, and fingolimod-P formed in situ may have direct effects on n

222 Its active form, fingolimod-phosphate (fingolimod-P), is a sphingosine 1-phosphate receptor (S1

223 oncentrations of the monoacyl monophosphates fingolimod phosphate, sphingosine 1-phosphate, and lysop

224 Its active form, fingolimod-phosphate (fingolimod-P), is a sphingosine 1-

225 Fingolimod potently inhibits the MS animal model, experi

226 Fingolimod prevents T-cell migration to inflammatory sit

227 cutaneous anaphylaxis) we topically applied fingolimod prophylactically, as well as after establishm

228 These cases provide evidence for a fingolimod rebound syndrome at a clinically relevant fre

229 In the treatment-naive subpopulation, fingolimod reduced ARR and n/neT2 lesions by 85.8% and 5

230 In a transient mouse model, fingolimod reduced infarct size, neurological deficit, e

231 In the clinical trials that led to approval, fingolimod reduced not only acute relapses and magnetic

232 tration of the immunosuppressant drug FTY720/fingolimod reduced ORMDL3 expression and ceramide levels

233 Fingolimod reduced the annualised rate of formation of n

234 ccomplished with epicutaneous application of fingolimod resolving histamine-induced and allergen-indu

235 These protective effects of fingolimod result in an increased life span of twitcher

236 Fingolimod's mechanism of action in MS is not known with

237 Fingolimod's unique mechanism of action distinguishes it

238 Although S1P and phospho-fingolimod share the same structural elements of a zwitt

239 S1P(1) (S1P receptor-1) modulators including fingolimod show promise for the treatment of ischemic an

240 Treatment with natalizumab and fingolimod showed different compartmental changes in pro

241 tting multiple sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and

242 Fingolimod significantly decreased edema, apoptosis and

243 In long-term experiments, fingolimod significantly improved myocardial salvage, re

244 Fingolimod significantly reduced MRI activity and ARBA f

245 ts show that treatment of twitcher mice with fingolimod significantly rescued myelin levels compared

246 different preferential use of rituximab and fingolimod (Stockholm, n = 156, fingolimod 51%; Gothenbu

247 In this study, we found that although fingolimod strongly and disproportionally reduced cTfh c

248 ch of the newly approved agents-natalizumab, fingolimod, teriflunomide, dimethyl fumarate, and alemtu

249 ificant prognostic factor for relapse during fingolimod therapy (odds ratio, 3.80; P = .05).

250 atient's VZV immune status before initiating fingolimod therapy and immunization for patients suscept

251 An ophthalmic examination before initiating fingolimod therapy and regular follow-up eye examination

252 nd regular follow-up eye examinations during fingolimod therapy are recommended.

253 1P1-deficient mice as well as MS patients on fingolimod therapy had an activated phenotype and were m

254 ults support a continued effect of long-term fingolimod therapy in maintaining a low rate of disease

255 tients relapsed during the first 6 months of fingolimod therapy.

256 Finally, therapeutic administration of fingolimod to EAE mice hampered astrocyte activation and

257 Fingolimod-treated EAE mice accumulate (18)F-FAC in the

258 Fingolimod-treated EAE mice were imaged with (18)F-FAC P

259 is (EAE) spinal cord, and the spinal cord of fingolimod-treated EAE mice.

260 ssed, 19 confirmed ME cases were observed in fingolimod-treated groups (0.5 mg: n = 4, 0.3%; 1.25 mg:

261 as accompanied by decreased inflammation, as fingolimod-treated mice had fewer activated neutrophils,

262 Fingolimod-treated mice showed a smaller infarct and per

263 Twice as many IFN beta-1a-treated than fingolimod-treated patients had worse EDSS scores at stu

264 y was reflected by an increased life span of fingolimod-treated twitcher mice.

265 ely 50% in the first year after switching to fingolimod treatment (44.3% to 66.0%).

266 in the combined T2 lesion area after 6 mo of fingolimod treatment (P = 0.040) but not in the areas of

267 In short-term experiments, fingolimod treatment activated the cardioprotective repe

268 High-dose fingolimod treatment administered before disease onset r

269 Fingolimod treatment also induced EAE in a disease-resis

270 the present investigation of the efficacy of fingolimod treatment for established disease, single-dos

271 Specifically, fingolimod treatment led to a significant reduction in L

272 highlight that rebound events after ceasing fingolimod treatment may happen even with short washout

273 hermore, these data provide insight into how fingolimod treatment might exacerbate CNS neuroinflammat

274 al PET can be used to evaluate the effect of fingolimod treatment on microglial activation.

275 Fingolimod treatment reduced microglial/macrophage activ

276 of severe disease reactivation after ceasing fingolimod treatment using search terms fingolimod and e

277 Of the 46 patients that stopped fingolimod treatment within the 2-year period, 5 (10.9%)

278 w severe neurological symptoms after ceasing fingolimod treatment, with the development of multiple n

279 tified who experienced rebound after ceasing fingolimod treatment.

280 d severe relapse 4 to 16 weeks after ceasing fingolimod treatment.

281 Occurrence of rebound after ceasing fingolimod treatment.

282 rongly and disproportionally decreased after fingolimod treatment.

283 High learners benefited more from fingolimod treatment.

284 rformed at baseline and after 8 and 24 wk of fingolimod treatment.

285 ns of S1P1 and potential impact of long term fingolimod use on Th17 and Treg cell biology and general

286 ceptor 1 (S1PR1) antagonists, such as FTY720/fingolimod, used clinically for non-pain conditions, are

287 FTY720/fingolimod, used for treatment of multiple sclerosis, is

288 (-0.48% vs -0.80%, p=0.014) were lower with fingolimod versus IFN beta-1a, the latter partially due

289 d superior efficacy and comparable safety of fingolimod versus interferon beta-1a (IFN beta-1a) in pa

290 natural mutation in the galc gene were given fingolimod via drinking water (1 mg/kg/d).

291 ated using both in vivo and ex vivo imaging (fingolimod vs. vehicle treatment, P < 0.0001).

292 mean washout period before the initiation of fingolimod was 2.3 +/- 1.1 mo.

293 Fingolimod was associated with a high risk of treatment

294 In this study, switching from natalizumab to fingolimod was associated with a risk of MS reactivation

295 While the phosphorylated metabolite of fingolimod was found to be a nonselective S1P receptor a

296 tients for whom a switch from natalizumab to fingolimod was planned.

297 FTY-720 (Fingolimod) was one of the first compounds authorized fo

298 Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit wit

299 ntially better safety profiles compared with fingolimod were tested in patients with relapsing multip

300 to 0.2 on natalizumab and from 1.3 to 0.4 on fingolimod, with 50% relative postswitch difference in r